The Influence of Antenatal Oral Iron and Folic Acid Side Effects on Supplementation Duration in Low-Resource Rural Kenya: A Cross-Sectional Study
Journal of Pregnancy · 11.05.2020 · 2020 · 1-7
DOI: 10.1155/2020/9621831 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Journal of Pregnancy, erschienen am 11.05.2020. Verfasst von Shadrack Oiye und 3 weiteren Autor:innen. Beteiligte Einrichtung: Intergovernmental Authority on Development (IGAD), Djibouti. Hauptthemen laut MEDLINE: Dietary Supplements, Health Resources. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Undesirable effects of a daily regimen of iron and folic acid ingested jointly (iron-folate) are potential disincentives to optimal antenatal supplementation. We intended to profile antenatal iron-folate side effects and elucidate their influence on supplementation duration in low-resource rural Kenya.
Methods
This was a cross-sectional descriptive study of randomly selected postnatal mothers of under-five-year-old children. Using a modified WHO Safe Motherhood Assessment standard questionnaire, they recalled the total number of days of antenatal iron-folate intake and the attendant supplement-attributed undesirable experiences. The analyses considered only participants who ingested the supplements in their immediate last pregnancies ( n = 277 ).
Results
About half of the study participants reported at least a side effect and a mean of 2.4 (SD 1.5) effects per person in the entire pregnancy period. Most common reported effects were chest pains (31.8%), constipation (28.5%), severe stomach pains (11.6%), and diarrhoea (11.6%). Mothers who reported at least a side effect ingested the supplements for ten days less compared to those who did not experience any effect ( p = 0.03 ); and a greater proportion of the former were primigravida ( p = 0.02 ) and used combined form of iron and folic acid ( p = 0.003 ). In a multivariate analysis, significant correlations with supplementation compliance (ingestion for 90+ days) were found only for nausea and severe stomach pain experiences ( r = − 0.1 , p = 0.04 ; r = 0.2 , p = 0.01 , resp.).
Conclusions
The commonness of undesirable experiences attributed to daily ingestion of 60 mg iron and 0.4 mg folic acid and their deterrence to longer supplementation durations suggest the need for considering a weekly intermittent regimen for some antenatal women in such set-ups. Our study demonstrated that potentially, more counselling on nausea as a side effect might be critical in advancing iron-folate supplementation compliance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Intergovernmental Authority on Development (IGAD), Djibouti.
- University of Nairobi Institute of Tropical and Infectious Diseases (UNITID), Nairobi, Kenya.
- Great Lakes University of Kisumu, Kisumu, Kenya.
- Department of Nursing, Kenya Medical Training Centre, Nairobi, Kenya.
- Department of Nutritional Sciences, Masinde Muliro University of Science and Technology, Kakamega, Kenya.
ORCID-Profile: Shadrack Oiye
Zitieren
APA
Oiye, S., Juma, M., Konyole, S., & Adan, F. (2020). The Influence of Antenatal Oral Iron and Folic Acid Side Effects on Supplementation Duration in Low-Resource Rural Kenya: A Cross-Sectional Study. Journal of Pregnancy, 2020, 1-7. https://doi.org/10.1155/2020/9621831
Vancouver
Oiye S, Juma M, Konyole S, Adan F. The Influence of Antenatal Oral Iron and Folic Acid Side Effects on Supplementation Duration in Low-Resource Rural Kenya: A Cross-Sectional Study. Journal of Pregnancy. 2020;2020:1-7. doi:10.1155/2020/9621831
BibTeX
@article{Oiye2020,
author = {Oiye, Shadrack and Juma, Margaret and Konyole, Silvenus and Adan, Fatuma},
title = {The Influence of Antenatal Oral Iron and Folic Acid Side Effects on Supplementation Duration in Low-Resource Rural Kenya: A Cross-Sectional Study},
journal = {Journal of Pregnancy},
year = {2020},
volume = {2020},
pages = {1--7},
doi = {10.1155/2020/9621831}
}
EUVIMED